Clinical utility of serum biomarkers for major psychiatric disorders

International Review of Neurobiology

Volumn 101, Issue , 2011, Pages 351-374

  Van Beveren, Nico J M ^a   Hoogendijk, Witte J G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Biomarkers; Bipolar disorder; Clinical psychiatry; Diagnosis; Schizophrenia

Indexed keywords

BIOLOGICAL MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUSTMENT DISORDER; BOOK; CLINICAL EVALUATION; CLINICAL FEATURE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE CLASSIFICATION; GENE EXPRESSION PROFILING; GENETIC MARKER; HUMAN; MENTAL DISEASE; MOLECULAR GENETICS; NONHUMAN; ONCOLOGY; PATIENT ASSESSMENT; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; SCHIZOPHRENIA; SERODIAGNOSIS; TREATMENT RESPONSE;

EID: 80055069383     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-387718-5.00014-6     Document Type: Chapter

References (80)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Press, Washington, DC. 4th ed.
2. Atkinson A.J., Colburn W.A., DeGruttola V.G., DeMets D.L., Downing G.J., Hoth D.F., Oates J.A., Peck C.C., Schooley R.T., Spilker B.A., Woodcock J., et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69:89-95. Biomarkers Definitions Working Group.
3. Brietzke E., Stertz L., Fernandes B.S., Kauer-Sant'anna M., Mascarenhas M., Escosteguy Vargas A., Chies J.A., Kapczinski F. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J. Affect. Disord. 2009, 116:214-217.
4. Brosen K., Otton S.V., Gram L.F. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. Clin. Pharmacol. Ther. 1986, 40:543-549.
5. Burstein H.J. The distinctive nature of HER2-positive breast cancers. N. Engl. J. Med. 2005, 20:1652-1654.
6. Cannon T.D., Cadenhead K., Cornblatt B., Woods S.W., Addington J., Walker E., Seidman L.J., Perkins D., Tsuang M., McGlashan T., Heinssen R. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch. Gen. Psychiatry 2008, 65:28-37.
7. Carroll B.J., Curtis G.C., Mendels J. Neuroendocrine regulation in depression. I. Limbic system-adrenocortical dysfunction. Arch. Gen. Psychiatry 1976, 33:1039-1044.
8. Catena-Dell'Osso M., Bellantuono C., Consoli G., Baroni S., Rotella F., Marazziti D. Inflammatory and neurodegenerative pathways in depression: a new avenue for antidepressant development?. Curr. Med. Chem. 2011, 18:245-255.
9. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell. Mol. Neurobiol. 2006, 26:363-382.
10. Craddock N., O'Donovan M.C., Owen M.J. Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophr. Bull. 2006, 32:9-16.
11. Cunha A.B., Frey B.N., Andreazza A.C., Goi J.D., Rosa A.R., Gonclaves C.A., Santin A., Kapczinski F. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci. Lett. 2006, 398:215-219.
12. Dalmau J., Rosenfeld M.R. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008, 7:327-340.
13. Dalmau J., Tüzün E., Wu H.Y., Masjuan J., Rossi J.E., Voloschin A., Baehring J.M., Shimazaki H., Koide R., King D., Mason W., Sansing L.H., et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann. Neurol. 2007, 61:25-36.
14. Davis K.L., Stewart D.G., Friedman J.I., Buchsbaum M., Harvey P.D., Hof P.R., Buxbaum J., Haroutunian V. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch. Gen. Psychiatry 2003, 60:443-456.
15. de Oliveira G.S., Ceresér K.M., Fernandes B.S., Kauer-Sant'Anna M., Fries G.R., Stertz L., Aguiar B., Pfaffenseller B., Kapczinski F. Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. J. Psychiatr. Res. 2009, 43:1171-1174.
16. Desmedt C., Sperinde J., Piette F., Huang W., Jin X., Tan Y., Durbecq V., Larsimont D., Giuliani R., Chappey C., Buyse M., Winslow J., et al. Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH. Diagn. Mol. Pathol. 2009, 18:22-29.
17. Domenici E., Willé D.R., Tozzi F., Prokopenko I., Miller S., McKeown A., Brittain C., Rujescu D., Giegling I., Turck C.W., Holsboer F., Bullmore E.T., et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One 2010, 5(2):e9166.
18. Drexhage R.C., Knijff E.M., Padmos R.C., Heul-Nieuwenhuijzen L., Beumer W., Versnel M.A., Drexhage H.A. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev. Neurother. 2010, 10:59-76.
19. Fernandez-Egea E., Bernardo M., Parellada E., Justicia A., Garcia-Rizo C., Esmatjes E., Conget I., Kirkpatrick B. Glucose abnormalities in the siblings of people with schizophrenia. Schizophr. Res. 2008, 103:110-113.
20. Fernandez-Egea E., Bernardo M., Donner T., Conget I., Parellada E., Justicia A., Esmatjes E., Garcia-Rizo C., Kirkpatrick B. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br. J. Psychiatry 2009, 194:434-438.
21. Frommberger U.H., Bauer J., Haselbauer P., Fräulin A., Riemann D., Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur. Arch. Psychiatry Clin. Neurosci. 1997, 247:228-233.
22. Galatzer-Levy I.R., Galatzer-Levy R.M. The revolution in psychiatric diagnosis: problems at the foundations. Perspect. Biol. Med. 2007, 50:161-180.
23. Garey L. When cortical development goes wrong: schizophrenia as a neurodevelopmental disease of microcircuits. J. Anat. 2010, 217:324-333.
24. Gold P.W., Licinio J., Wong M.L., Chrousos G.P. Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Ann. N. Y. Acad. Sci. 1995, 771:716-729.
25. Guest P.C., Wang L., Harris L.W., Burling K., Levin Y., Ernst A., Wayland M.T., Umrania Y., Herberth M., Koethe D., van Beveren J.M., Rothermundt M., et al. Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naive schizophrenia patients. Mol. Psychiatry 2010, 15:118-119.
26. Henry L.P., Amminger G.P., Harris M.G., Yuen H.P., Harrigan S.M., Prosser A.L., Schwartz O.S., Farrelly S.E., Herrman H., Jackson H.J., McGorry P.D. The EPPIC follow-up study of first-episode psychosis: longer-term clinical and functional outcome 7years after index admission. J. Clin. Psychiatry 2010, 71:716-728.
27. Holsboer F., Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr. Rev. 1996, 17:187-205.
28. Holt R.I., Peveler R.C., Byrne C.D. Schizophrenia, the metabolic syndrome and diabetes. Diabet. Med. 2004, 21:515-523.
29. Horrobin D.F. Niacin flushing, prostaglandin E3 and evening primrose oil. A possible objective test for monitoring therapy in schizophrenia. J. Orthomolec. Psychiatr. 1980, 9:33-34.
30. Insel T.R. Rethinking schizophrenia. Nature 2010, 468:187-193.
31. Kanner L., Eisenberg L. Early infantile autism, 1943-1955. Psychiatr. Res. Rep. Am. Psychiatr. Assoc. 1957, 7:55-65.
32. Karoutzou G., Emrich H.M., Dietrich D.E. The myelin-pathogenesis puzzle in schizophrenia: a literature review. Mol. Psychiatry 2008, 13:245-260.
33. Kim Y.K., Myint A.M., Verkerk R., Scharpe S., Steinbusch H., Leonard B. Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology 2009, 59:123-129.
34. King B.H., Lord C. Is schizophrenia on the autism spectrum?. Brain Res. 2011, 1380:34-41.
35. Koehler K., Guth W., Grimm G. First-rank symptoms of schizophrenia in Schneider-oriented German centers. Arch. Gen. Psychiatry 1977, 34:810-813.
36. Kooy F.H. Hyperglycemia inmental disorders. Brain 1919, 42:214-289.
37. Kraepelin E. Dementia Praecox and Paraphrenia 1971, Robert E Krieger Publishing Co., Huntington, NY.
38. Kunz M., Ceresér K.M., Goi P.D., Fries G.R., Teixeira A.L., Fernandes B.S., Belmonte-de-Abreu P.S., Kauer-Sant'anna M., Kapczinski F., Gama C.S. Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Rev. Bras. Psiquiatr. 2011, Mar 18 [Epub ahead of print].
39. Laughren T.P. What's next after 50years of psychiatric drug development: an FDA perspective. J. Clin. Psychiatry 2010, 71:1196-1204.
40. Lewis D.A., Mirnics K. Transcriptome alterations in schizophrenia: disturbing the functional architecture of the dorsolateral prefrontal cortex. Prog. Brain Res. 2006, 158:141-152.
41. Liebzeit K.A., Markowitz J.S., Caley C.F. New onset diabetes and atypical antipsychotics. Eur. Neuropsychopharmacol. 2001, 11:25-32.
42. Lin A., Kenis G., Bignotti S., Tura G.J., De Jong R., Bosmans E., Pioli R., Altamura C., Scharp S., Maes M. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr. Res. 1998, 32:9-15.
43. Maes M., Bocchio Chiavetto L., Bignotti S., Battisa Tura G., Pioli R., Boin F., Kenis G., Bosmans E., de Jongh R., Lin A., Racagni G., Altamura C.A. Effects of atypical antipsychotics on the inflammatory response system in schizofrenia patients resistant to treatment with typical neuroleptics. Eur. Neuropsychopharmacol. 2000, 10:119-124.
44. Martins-de-Souza D., Harris L.W., Guest P.C., Bahn S. The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics. Antioxid. Redox Signal. 2010, Dec 2 [Epub ahead of print].
45. McGorry P.D., Yung A.R., Bechdolf A., Amminger P. Back to the future: prediking and reshaping the course of psychotic disorder. Arch. Gen. Psychiatry 2008, 65:25-27.
46. McMahon F.J., Buervenich S., Charney D., Lipsky R., Rush A.J., Wilson A.F., Sorant A.J., Papanicolaou G.J., Laje G., Fava M., Trivedi M.H., Wisniewski S.R., et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am. J. Hum. Genet. 2006, 78:804-814.
47. Meyer J.M. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1year. J. Clin. Psychiatry 2002, 63:425-433.
48. Monteleone P., Fabrazzo M., Tortorella A., Maj M. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Res. 1997, 7:11-17.
49. Naudin J., Capo C., Giusano B., Moge J.L., Azorin J.M. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia?. Schizophr. Res. 1997, 26:227-233.
50. Nemeroff C.B., Vale W.W. The neurobiology of depression: inroads to treatment and new drug discovery. J. Clin. Psychiatry 2005, 66(Suppl. 7):5-13.
51. Nestler E.J., Hyman S.E. Animal models of neuropsychiatric disorders. Nat. Neurosci. 2010, 13:1161-1169.
52. O'Brien S.M., Scully P., Scott L.V., Dinan T.G. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J. Affect. Disord. 2006, 90:263-267.
53. Pfohl B., Sherman B., Schlechte J., Winokur G. Differences in plasma ACTH and cortisol between depressed patients and normal controls. Biol. Psychiatry 1985, 20:1055-1072.
54. Ray S., Britschgi M., Herbert C., Takeda-Uchimura Y., Boxer A., Blennow K., Friedman L.F., Galasko D.R., Jutel M., Karydas A., Kaye J.A., Leszek J., et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 2007, 13:1359-1362.
55. Ryan M.C., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry 2003, 160:284-289.
56. Sadler J.Z. Values and Psychiatric Diagnosis 2005, Oxford University Press, Oxford, UK.
57. Sauer J.M., Ring B.J., Witcher J.W. Clinical pharmacokinetics of atomoxetine. Clin. Pharmacokinet. 2005, 44:571-590.
58. Schwarz E., Izmailov R., Spain M., Barnes A., Mapes J.P., Guest P.C., Rahmoune H., Pietsch S., Leweke F.M., Rothermundt M., Steiner J., Koethe D., et al. Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark. Insights 2010, 5:39-47.
59. Schwarz E., Guest P.C., Rahmoune H., Harris L.W., Wang L., Leweke F.M., Rothermundt M., Bogerts B., Koethe D., Kranaster L., Ohrmann P., Suslow T., et al. Identification of a biological signature for schizophrenia in serum. Mol. Psychiatry 2011, Apr 12 [Epub ahead of print].
60. Serretti A., Kato M., De Ronchi D., Kinoshita T. Meta-analysis of serotonine transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol. Psychiatry 2007, 12:247-257.
61. Smesny S., Klemm S., Stockebrand M., Grunwald S., Gerhard U.J., Rosburg T., Sauer H., Blanz B. Endophenotype properties of niacin sensitivity as marker of impaired prostaglandin signalling in schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids 2007, 77:79-85.
62. Spelman L.M., Walsh P.I., Sharifi N., Collins P., Thakore J.H. Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet. Med. 2007, 24:481-485.
63. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., Cichon S., Rujescu D., Werge T., Pietiläinen O.P., Mors O., Mortensen P.B., Sigurdsson E., Gustafsson O., et al. Common variants conferring risk of schizophrenia. Nature 2009, 460:744-747.
64. Steiner J., Walter M., Guest P., Myint A.M., Schiltz K., Panteli B., Brauner M., Bernstein H.G., Gos T., Herberth M., Schroeter M.L., Schwarz M.J., et al. Elevated S100B levels in schizophrenia are associated with insulin resistance. Mol. Psychiatry 2010, 15:3-4.
65. Stokes P.E., Stoll P.M., Koslow S.H., Maas J.W., Davis J.M., Swann A.C., Robins E. Pretreatment DST and hypothalamic-pituitary-adrenocortical function in depressed patients and comparison groups. A multicenter study. Arch. Gen. Psychiatry 1984, 41:257-267.
66. Takahashi N., Sakurai T., Davis K.L., Buxbaum J.D. Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia. Prog. Neurobiol. 2011, 93:13-24.
67. Theodoropoulou S., Spanakos G., Baxevanis C.N., Economou M., Gritzapis A.D., Papamichail M.P., Stefanis C.N. Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophr. Res. 2001, 47:13-25.
68. Tramontina J.F., Andreazza A.C., Kauer-Sant'anna M., Stertz L., Goi J., Chiarani F., Kapczinski F. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci. Lett. 2009, 452:111-113.
69. Valk P.J., Verhaak R.G., Beijen M.A., Erpelinck C.A., van Waalwijk Barjesteh, van Doorn-Khosrovani S., Boer J.M., Beverloo H.B., Moorhouse M.J., van der Spek P.J., Lowenberg B., Delwel R. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 2004, 350:1617-1628.
70. van Beveren N.J., van der Spelt J.J., de Haan L., Fekkes D. Schizophrenia-associated neural growth factors in peripheral blood. A review. Eur. Neuropsychopharmacol. 2006, 16:469-480.
71. Van Nimwegen L.J., Storosum J.G., Blumer R.M., Allick G., Venema H.W., de Haan L., Becker H., van Amelsvoort T., Ackermans M.T., Fliers E., Serlie M.J., Sauerwein H.P. Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J. Clin. Endocrinol. Metab. 2008, 93:572-577.
72. Van Os J., Hanssenm M., Bijl R.V., Ravelli A. Straus (1969) revisited; a psychosis continuum in the general population?. Schizophr. Res. 2000, 29:11-20.
73. Van Praag H.M. Over the mainstream: diagnostic requirements for biological psychiatric research. Psychiatry Res. 1997, 72:201-212.
74. Van Praag H.M. Nosologomania: a disorder of psychiatry. World J. Biol. Psychiatry 2000, 1:151-158.
75. Van Praag H.M. Past expectations, present disappointments, future hopes or psychopathology as the rate-limiting step of progress in psychopharmacology. Hum. Psychopharmacol. 2001, 16:3-7.
76. Venkatasubramanian G., Chittiprol S., Neelakantachar N., Naveen M.N., Thirthall J., Gangadhar B.N., Shetty K.T. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am. J. Psychiatry 2007, 164:1557-1560.
77. Vreeburg S.A., Hoogendijk W.J., van Pelt J., Derijk R.H., Verhagen J.C., van Dyck R., Smit J.H., Zitman F.G., Penninx B.W. Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study. Arch. Gen. Psychiatry 2009, 66:617-626.
78. Williams H.J., Craddock N., Russo G., Hamshere M.L., Moskvina V., Dwyer S., Smith R.L., Green E., Grozeva D., Holmans P., Owenm M.J., O'Donovan M.C. Most genome-wide significant susceptibility loci for schizophrenia and bipolar disorder reported to date cross-traditional diagnostic boundaries. Hum. Mol. Genet. 2011, 20:387-391.
79. Woods S.W., Addington J., Cadenhead K.S., Cannon T.D., Cornblatt B.A., Heinssen R., Perkins D.O., Seidman L.J., Tsuang M.T., Walker E.F., McGlashan T.H. Validity of the prodromal risk syndrome for first psychosis: findings from the north American prodrome longitudinal study. Schizophr. Bull. 2009, 35:894-908.
80. Yung A.R., Nelson B., Stanford C., Simmons M.B., Cosgrave E.M., Killackey E., Phillips L.J., Bechdolf A., Buckby J., McGorry P.D. Validationof " prodromal" criteria to detect individuals at ultra high risk of psychosis: 2year follow-up. Schizophr. Res. 2008, 105:10-17.